Table 1.

Summary of patients with myeloproliferative neoplasms with nonsynonymous LNK mutations.

LNK mutation	Domains affected	Diagnosis	Study
DEL	PH + SH2	PMF	[Oh et al. 2010]
E208Q	PH	ET	[Oh et al. 2010]
E208X	PH + SH2	JAK2-negative erythrocytosis	[Lasho et al. 2010]
A215V	PH	JAK2-negative erythrocytosis	[Lasho et al. 2010]
A215V	PH	Post-PMF AML1	[Pardanani et al. 2010]
A215V	PH	Post-PMF AML1	[Pardanani et al. 2010]
G220R	PH	PMF2	[Pardanani et al. 2010]
G220V	PH	PMF2	[Pardanani et al. 2010]
A223V D234N	PH	Post-PMF AML3	[Pardanani et al. 2010]
G229S	PH	Post-PMF AML4	[Pardanani et al. 2010]
685–691_delGGCCCCG; 955_delA	PH + SH2; SH2	PMF/AML5 PMF/AML5	[Pardanani et al. 2010]

¹Mutation not present at the chronic phase.

²Mutation not detected at the blast phase.

³Both mutations detected in the same patient and not present in the chronic phase.

⁴Chronic phase samples not available for analysis.

⁵Both deletion mutations detected in the same patient and present in both chronic and blast phases.

PH, pleckstrin homology; SH2, Src homology 2; PMF, primary myelofibrosis; ET, essential thrombocythemia; AML, acute myeloid leukemia.